We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fluorescence-Based Photodynamic Product Detects Premalignant/Malignant Colorectal Cancer Lesions

By Labmedica staff writers
Posted on 28 May 2008
A new fluorescence-based photodynamic diagnostic (PDD) product has produced excellent results in a clinical trial evaluating its potential for detecting premalignant/malignant lesions in patients with suspected colorectal cancer.

A dose-finding phase I/II study of the new product, Lumacan, was performed at two hospitals in Germany using fluorescence diagnosis in 38 patients with suspected colorectal cancer. More...
Patients received local instillation of Lumacan in the colon before proceeding with standard colonoscopy using both white and blue (fluorescence) light. The light-sensitive active ingredient in Lumacan, hexalevulinate (HAL), is rapidly accumulated in metabolically active cancerous and precancerous cells, and it fluoresces red when illuminated with blue light.

The results of the study found that of the 91 lesions identified in 25 patients with suspected colorectal cancer using the gold standard approach of tissue histology, 90 lesions were detected using PDD examination with Lumacan, while only 55 lesions were detected using white-light endoscopy. The approach using Lumacan therefore identified 36 more polyps than with the standard clinical procedure of white-light endoscopic imaging, an improvement of approximately 65%. No systemic or local side effects related to the use of Lumacan were reported.

The principle investigator of the trial, Dr. Brigitte Mayinger from the Hospital Munich-Pasing, (Munich, Germany) said, "In this trial, Lumacan conclusively demonstrated its ability to induce specific and selective fluorescence in colorectal lesions thereby significantly increasing the lesion detection rate in patients with colorectal adenoma and early carcinoma compared with standard methods. This new photodynamic diagnosis technique can also detect the flat, nonvisible lesions and hidden polyps that are difficult to observe and which if missed can lead to recurrent or progressive disease.”

Lumacan (hexaminolevulinate) is being developed by Photocure (Oslo, Norway) to improve standard colonoscopy in patients with suspected colorectal cancer. This new product is based on the Hexvix product, which is already approved in Europe for the improved diagnosis of bladder and cancer lesions.

The final study results were presented at Digestive Disease Week (DDW) in San Diego (CA, USA) on May 21, 2008, by Dr. Mayinger.


Related Links:
Photocure

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.